Navigation Links
Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
Date:11/15/2011

HOBOKEN, N.J. and PHILADELPHIA, Nov. 15, 2011 /PRNewswire/ -- Niiki Pharma Inc. presented the results of preclinical combination studies of its lead product, NKP-1339, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in San Francisco, CA, November 12-16, 2011.

The data were presented as a poster, titled "NKP-1339 synergistic activity in both in vitro and in vivo preclinical models highlights the therapeutic opportunity for NKP-1339 combination trials with a broad range of anti-tumor agents."

Data summary:

  • In vitro combination studies were performed in breast, colon, lung, gastric, prostate, pancreatic and liver tumor cell lines.  NKP-1339 was tested in combination with cisplatin, oxaliplatin, 5-FU, docetaxel, doxorubicin, gemcitabine, erlotinib or sorafenib as appropriate for each tumor cell type. Synergistic cytotoxicity was seen with all combinations tested.
  • In vivo gastric carcinoma xenograft model was tested with NKP-1339 in combination with cisplatin. The combination showed significant (P<0.05) tumor growth delay and extended survival when compared to the single agent activity for either compound.

  • The broad synergism of NKP-1339 across the tested anti-neoplastic agents is consistent with its proposed mechanism of action through inhibition of the GRP78 pathway.

    "The synergy we have demonstrated in both in vitro and in vivo settings suggests that NKP-1339 will be effective in combination with these anti-cancer agents in the clinical setting. The favorable efficacy and safety profile observed to date in our ongoing single agent NKP-1339 Phase I trial warrants its investigation in combination studies for our next round of clinical trials," noted Angela Ogden MD, Chief Medical Officer at Niiki Pharma.

    About NKP-1339NKP-1339 is a first-in-class small molecule anti-cancer compound. NKP-1339 down-regulates the
    '/>"/>

    SOURCE Niiki Pharma Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
    2. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
    3. Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
    4. CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
    5. Qualitest Pharmaceuticals Receives FDA Approval for Acetaminophen and Codeine Phosphate Oral Solution USP, 120mg/12mg per 5mL
    6. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
    7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2011 Results
    8. E7: The Outlook for Pharmaceuticals to 2012
    9. The Outlook for Pharmaceuticals in Central Asia
    10. The Outlook for Pharmaceuticals in Northern Europe
    11. Emerging Pharmaceutical Markets Globally
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
    (Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
    (Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
    Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
    ... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
    ... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
    Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
    (Date:9/1/2015)... ... September 01, 2015 , ... ... to announce its new fall collection. Every customer who buys an Earth Brand ... the company’s environmental partnership with Trees for the Future, a nonprofit dedicated to ...
    (Date:9/1/2015)... ... ... Celebrity hairstylist and Beauty Gives Back Art Team member Ted Gibson in ... Oct. 1, at the La Valencia Hotel. The presentation, on the eve of Fashion ... professional hair, makeup and nail design. , The evening of beauty and fashion ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... options to efficiently cure and prevent different malignancies. Some options for cancer ... pathophysiological properties due to which distinctive approach is necessary for effective treatment. ...
    (Date:9/1/2015)... ... September 01, 2015 , ... Virginia ... Machine,” is still strongly maintaining her firm’s success in the hair care and ... her upcoming city-to-city tour, Ellis will be providing “Look and learn” live demonstrations, ...
    (Date:9/1/2015)... ... 01, 2015 , ... PetPace, the provider of an innovative ... activity, today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Practice Management Software packages in the US. Practice Management Software helps veterinarians manage ...
    Breaking Medicine News(10 mins):Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2
    ... powers introduced by the government to enable specially trained ... been successfully adopted, according to a new report. ... Keele found widespread acceptance of the new powers among ... for the type of medical conditions being treated. ...
    ... HealthDay Reporter , MONDAY, May 9 (HealthDay News) -- ... nervous system disease known as amyotrophic lateral sclerosis (ALS), British ... does not mean people with long ring fingers will develop ... risk for it. "We have not done a study ...
    ... By Alan Mozes HealthDay Reporter , MONDAY, ... link specific behaviors and health conditions to the onset of ... anything you do or don,t do will prevent the brain ... The U.S. National Institutes of Health convened a ...
    ... at Scripps Institution of Oceanography at UC San Diego ... known to produce substances potentially useful against human diseases. ... the oldest forms of life on the planet. At ... to humans and animals. But despite the recognized capability ...
    ... MONDAY, May 9 (HealthDay News) -- Could gastric bypass weight-loss ... That,s the finding from a group of Swedish researchers who ... the Digestive Disease Week conference in Chicago. A team ... patients who underwent primary bariatric surgery between 1980 and 2006. ...
    ... MONDAY, May 9 (HealthDay News) -- Overdiagnosis and overtreatment of ... to the large increase in the use of computed tomography ... embolism (PE) is a potentially life-threatening blood clot in the ... PE and its use has grown rapidly, according to background ...
    Cached Medicine News:Health News:Wide-reaching report finds strong support for nurse and pharmacist prescribing 2Health News:Ring Finger Length Linked to ALS, Study Suggests 2Health News:Ring Finger Length Linked to ALS, Study Suggests 3Health News:Little Evidence That Diet, Lifestyle Cuts Alzheimer's Risk 2Health News:Little Evidence That Diet, Lifestyle Cuts Alzheimer's Risk 3Health News:Genome of marine organism reveals hidden secrets 2Health News:Genome of marine organism reveals hidden secrets 3Health News:Risk for Problem Drinking May Rise After Gastric Bypass 2Health News:Scan Technology Tied to Overtreatment of Clots in Lungs 2
    ... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
    ... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
    Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
    Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
    Medicine Products: